AR084217A1 - Inhibidores macrociclicos de virus flaviviridae - Google Patents
Inhibidores macrociclicos de virus flaviviridaeInfo
- Publication number
- AR084217A1 AR084217A1 ARP110104596A ARP110104596A AR084217A1 AR 084217 A1 AR084217 A1 AR 084217A1 AR P110104596 A ARP110104596 A AR P110104596A AR P110104596 A ARP110104596 A AR P110104596A AR 084217 A1 AR084217 A1 AR 084217A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- nhc
- alkynyl
- alkenyl
- Prior art date
Links
- 241000710781 Flaviviridae Species 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 3
- 125000004450 alkenylene group Chemical group 0.000 abstract 3
- 125000004419 alkynylene group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan compuestos de fórmula (1) y composiciones farmacéuticas. Los compuestos, las composiciones y los métodos proporcionados son útiles para el tratamiento de las infecciones por virus Flaviviridae, en particular las infecciones por hepatitis C.Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de dicho compuesto, en donde: X es O, S o NR1; cada R1 es independientemente H, alquilo C1-4 opcionalmente sustituido, alquenilo C2-4 opcionalmente sustituido o alquinilo C2-4 opcionalmente sustituido; cada R2 o R3 es independientemente H, alquilo C1-4 opcionalmente sustituido, alquenilo C2-4 opcionalmente sustituido, alquinilo C2-4 opcionalmente sustituido, halógeno, ciano, C(O)R1, C(O)OR1 o CON(R1)2; o R2 y R3, cuando se toman junto con el carbono al cual ambos están unidos, forman -C(=O)-, -C(=S)- o -C(=NR1)-; A es O, S(O)n, NR4 o alquileno C1-2 opcionalmente sustituido; cada n es independientemente 0, 1 ó 2; cada R4 es independientemente H, alquilo C1-4 opcionalmente sustituido, alquenilo C2-4 opcionalmente sustituido, alquinilo C2-4 opcionalmente sustituido, ciano, C(O)R7, C(O)OR7, CON(R7)2, S(O)R16, S(O)2R16, S(O)2OR7 o S(O)2N(R7)2; R5 es arilalquilo C0-4 opcionalmente sustituido, heterociclilalquilo C0-4 opcionalmente sustituido, cicloalquilalquilo C0-4 opcionalmente sustituido o alquilo C1-8 opcionalmente sustituido en donde cada arilalquilo C0-4 opcionalmente sustituido, cicloalquilalquilo C0-4 opcionalmente sustituido o alquilo C1-8 opcionalmente sustituido está sustituido con uno o varios R6; cada R6 es independientemente halo, CF3, OR4, CH2OR4, SR4, S(O)R16, S(O)2R16, N(R1)2, NHCOR1, NHC(O)OR1, NHC(O)N(R1)2, NHC(NR1)R1, NHC(NR1)N(R1)2, C(O)R1, C(O)N(R1)2, CO2R1, S(O)2OR1, S(O)2N(R1)2, NHS(O)2OR1, NHS(O)2R16, NHS(O)2N(R1)2, P(O)(OR1)2, P(O)(OR1)(N(R1)2), P(O)(R7)(OR1), OP(O)(OR1)2, OP(O)(OR1)(N(R1)2), NHP(O)(OR1)2 o NHP(O)(OR1)(N(R1)2); cada R7 es H, alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilalquilo C1-4 opcionalmente sustituido, cicloalquilalquilo C1-4 opcionalmente sustituido o heterociclilalquilo C1-4 opcionalmente sustituido; cada R16 es alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilalquilo C1-4 opcionalmente sustituido, cicloalquilalquilo C1-4 opcionalmente sustituido o heterociclilalquilo C1-4 opcionalmente sustituido; cada R8, R8b, R9 o R9b es independientemente H, alquilo C1-8 opcionalmente sustituido, alquenilo C2-8 opcionalmente sustituido, alquinilo C2-8 opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilalquilo C1-4 opcionalmente sustituido, cicloalquilalquilo C1-4 opcionalmente sustituido, heterociclilalquilo C1-4 opcionalmente sustituido, OR4, SR4, S(O)R16, S(O)2R16 o N(R4)2; con la condición de que cada R8, R8b, R9 y R9b no sea H; y con la condición de que, cuando R9 es OH y cada R8b y R9b son H, entonces R8 no sea un resto del grupo de fórmulas (2); A1 es alquileno C2-5 opcionalmente sustituido, alquenileno C2-5 opcionalmente sustituido o alquinileno C2-5 opcionalmente sustituido, arilalquileno C0-2 opcionalmente sustituido, cicloalquilalquileno C0-2 opcionalmente sustituido o heterociclilalquileno C0-2 opcionalmente sustituido; en donde un átomo de carbono sp3 de dicho alquileno C2-5 opcionalmente sustituido, alquenileno C2-5 opcionalmente sustituido, alquinileno C2-5 opcionalmente sustituido, arilalquileno C0-2 opcionalmente sustituido, cicloalquilalquileno C0-2 opcionalmente sustituido o heterociclilalquileno C0-2 opcionalmente sustituido está opcionalmente reemplazado por O, S(O)n o NR4; A2 es arileno opcionalmente sustituido, heteroarileno opcionalmente sustituido, heterocicleno opcionalmente sustituido, cicloalquileno opcionalmente sustituido, alquileno C1-3 opcionalmente sustituido, alquenileno C2-3 opcionalmente sustituido o alquinileno C2-3 opcionalmente sustituido; R12 es H, alquilo C1-4 opcionalmente sustituido, alquenilo C2-4 opcionalmente sustituido o alquinilo C2-4 opcionalmente sustituido; cada Ra es independientemente H, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo, heterociclilo, arilalquilo C1-8, cicloalquilo o cicloalquilalquilo C1-8 y en donde, cuando R1, R2, R3, R4, R5, R7, R8, R9, R8b, R9b, R10, R11, R12, R13, R14, R15, R16, A, A1 ó A2 está sustituido, el sustituyente es, independientemente, uno o varios sustituyentes seleccionados del grupo que consiste en halo, CN, CF3, N3, N(Ra)2, SRa, ORa, Ra, NHCORa, NHC(O)ORa, NHC(O)N(Ra)2, NHC(NRa)Ra, NHC(NRa)N(Ra)2, C(O)Ra, C(O)N(Ra)2, CO2Ra, S(O)2ORa, S(O)2N(Ra)2, NHS(O)2ORa, NHS(O)2N(Ra)2, OP(O)(ORa)2, OP(O)(ORa)(N(Ra)2), NHP(O)(ORa)2 y NHP(O)(ORa)(N(Ra)2).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42207110P | 2010-12-10 | 2010-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084217A1 true AR084217A1 (es) | 2013-05-02 |
Family
ID=45464097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104596A AR084217A1 (es) | 2010-12-10 | 2011-12-07 | Inhibidores macrociclicos de virus flaviviridae |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8513184B2 (es) |
| EP (1) | EP2649076B1 (es) |
| JP (1) | JP5847193B2 (es) |
| KR (1) | KR20140031841A (es) |
| CN (1) | CN103403009B (es) |
| AR (1) | AR084217A1 (es) |
| AU (1) | AU2011338262B2 (es) |
| BR (1) | BR112013014063A2 (es) |
| CA (1) | CA2819824A1 (es) |
| EA (1) | EA026114B1 (es) |
| ES (1) | ES2536321T3 (es) |
| IL (1) | IL226739A (es) |
| MX (1) | MX2013006475A (es) |
| NZ (1) | NZ612159A (es) |
| PL (1) | PL2649076T3 (es) |
| PT (1) | PT2649076E (es) |
| SI (1) | SI2649076T1 (es) |
| TW (1) | TWI520966B (es) |
| UY (1) | UY33775A (es) |
| WO (1) | WO2012078915A1 (es) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2875718A1 (en) | 2012-06-08 | 2013-12-12 | Selcia Limited | Macrocyclic inhibitors of flaviviridae viruses |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| JP6209601B2 (ja) | 2012-06-08 | 2017-10-04 | ギリアード サイエンシーズ， インコーポレイテッド | フラビウイルス科ウイルスの大環状阻害剤 |
| SG11201604482QA (en) * | 2013-12-23 | 2016-07-28 | Gilead Sciences Inc | Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide |
| BR102015023450A2 (pt) | 2014-09-16 | 2016-04-12 | Gilead Sciences Inc | formas sólidas de um modulador do receptor semelhante a toll |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| SI3321265T1 (sl) | 2015-03-04 | 2020-07-31 | Gilead Sciences, Inc. | Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev |
| AU2016312508A1 (en) | 2015-08-26 | 2018-02-15 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| JP6746776B2 (ja) | 2016-09-02 | 2020-08-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体調節剤化合物 |
| IL308894A (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP3672970A1 (en) | 2017-08-22 | 2020-07-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| MY196582A (en) | 2018-02-13 | 2023-04-19 | Gilead Sciences Inc | PD-1/PD-L1 Inhibitors |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| CN112384505B (zh) | 2018-07-06 | 2025-05-27 | 吉利德科学公司 | 治疗性的杂环化合物 |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| PL3873903T3 (pl) | 2018-10-31 | 2024-05-20 | Gilead Sciences, Inc. | Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| US20210009718A1 (en) | 2019-06-25 | 2021-01-14 | Gilead Sciences, Inc. | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| BR112022008535A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras |
| CR20220241A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4567109A3 (en) | 2019-12-06 | 2025-09-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| EP4334325A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114796193B (zh) * | 2022-05-13 | 2023-07-18 | 黑龙江八一农垦大学 | 抗牛病毒性腹泻病毒的中药单体 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| BRPI0613142A2 (pt) | 2005-06-17 | 2010-12-21 | Novartis Ag | uso de sangliferina em hcv |
-
2011
- 2011-12-07 UY UY0001033775A patent/UY33775A/es not_active Application Discontinuation
- 2011-12-07 AR ARP110104596A patent/AR084217A1/es unknown
- 2011-12-08 ES ES11805697.7T patent/ES2536321T3/es active Active
- 2011-12-08 SI SI201130434T patent/SI2649076T1/sl unknown
- 2011-12-08 MX MX2013006475A patent/MX2013006475A/es active IP Right Grant
- 2011-12-08 PL PL11805697T patent/PL2649076T3/pl unknown
- 2011-12-08 AU AU2011338262A patent/AU2011338262B2/en not_active Ceased
- 2011-12-08 PT PT118056977T patent/PT2649076E/pt unknown
- 2011-12-08 WO PCT/US2011/064009 patent/WO2012078915A1/en not_active Ceased
- 2011-12-08 CN CN201180066396.4A patent/CN103403009B/zh not_active Expired - Fee Related
- 2011-12-08 KR KR1020137017607A patent/KR20140031841A/ko not_active Abandoned
- 2011-12-08 BR BR112013014063A patent/BR112013014063A2/pt not_active IP Right Cessation
- 2011-12-08 NZ NZ612159A patent/NZ612159A/en not_active IP Right Cessation
- 2011-12-08 EP EP11805697.7A patent/EP2649076B1/en active Active
- 2011-12-08 CA CA2819824A patent/CA2819824A1/en not_active Abandoned
- 2011-12-08 JP JP2013543356A patent/JP5847193B2/ja not_active Expired - Fee Related
- 2011-12-08 EA EA201390822A patent/EA026114B1/ru not_active IP Right Cessation
- 2011-12-08 US US13/315,069 patent/US8513184B2/en not_active Expired - Fee Related
- 2011-12-09 TW TW100145540A patent/TWI520966B/zh not_active IP Right Cessation
-
2013
- 2013-06-04 IL IL226739A patent/IL226739A/en active IP Right Grant
- 2013-07-15 US US13/942,501 patent/US8933015B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011338262B2 (en) | 2016-12-15 |
| US20130022573A1 (en) | 2013-01-24 |
| CA2819824A1 (en) | 2012-06-14 |
| EA026114B1 (ru) | 2017-03-31 |
| EP2649076B1 (en) | 2015-03-04 |
| IL226739A (en) | 2017-05-29 |
| UY33775A (es) | 2012-07-31 |
| US8513184B2 (en) | 2013-08-20 |
| NZ612159A (en) | 2015-07-31 |
| KR20140031841A (ko) | 2014-03-13 |
| MX2013006475A (es) | 2013-11-01 |
| JP2014503516A (ja) | 2014-02-13 |
| US20140023616A1 (en) | 2014-01-23 |
| WO2012078915A1 (en) | 2012-06-14 |
| TWI520966B (zh) | 2016-02-11 |
| AU2011338262A1 (en) | 2013-07-11 |
| US8933015B2 (en) | 2015-01-13 |
| EA201390822A1 (ru) | 2013-12-30 |
| HK1191000A1 (en) | 2014-07-18 |
| TW201307355A (zh) | 2013-02-16 |
| ES2536321T3 (es) | 2015-05-22 |
| PL2649076T3 (pl) | 2015-08-31 |
| CN103403009A (zh) | 2013-11-20 |
| PT2649076E (pt) | 2015-06-02 |
| EP2649076A1 (en) | 2013-10-16 |
| JP5847193B2 (ja) | 2016-01-20 |
| CN103403009B (zh) | 2016-01-13 |
| SI2649076T1 (sl) | 2015-07-31 |
| BR112013014063A2 (pt) | 2016-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084217A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| AR055395A1 (es) | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c | |
| AR070127A1 (es) | Pirrolo - pirimidinas y pirrolo -piridinas | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| AR058065A1 (es) | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. | |
| HRP20241482T1 (hr) | Kratki peptidni spoj prolina s modificiranim prstenom i njegova uporaba | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR071395A1 (es) | Analogos carba-nucleosidos 1'-sustituidos para tratamiento antiviral | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR061858A1 (es) | Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| AR080433A1 (es) | Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. | |
| AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
| AR038843A1 (es) | Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |